Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass
Status:
COMPLETED
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Human albumin is a widely used additive in cardiopulmonary bypass all around the world, but its effect on various outcomes has been debated. The goal of this observational study is to compare the effect of 100 ml 20% human albumin addition to cardiopulmonary bypass on pleural effusion development after open heart surgery.
The main question it aims to answer is:
Does albumin, in addition to cardiopulmonary bypass, reduce pleural effusion development after open heart surgery? Patients will go under elective open heart surgery. Investigators will compare pleural effusion volume on the first day after surgery between patients who received albumin and those who didn't.